Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Related Articles
Breaking the mold: Unconventional T cells in cancer therapy
Unconventional T cells, including invariant natural killer T (iNKT) cells, gamma delta (γδ) T cells, and mucosal-associated invariant T (MAIT) cells, play important roles in both innate…
Against the Wind
You do your best to protect your skin from the sun. But did you know Mother Nature ups the ante on windy days? Our experts…
EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC
The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.
How Ohio State cancer experts are working to prevent lymphoma in Ethiopia
Ohio State cancer doctors are taking their expertise to Ethiopia to help prevent lymphoma through a program focused on treatment, vaccination and education.
China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC
The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.
Defeating lethal cancer: Interrupting the ecologic and evolutionary basis of death from malignancy
Despite the advances in cancer prevention, early detection, and treatments, all of which have led to improved cancer survival, globally, there is an increased incidence…
Urine test may detect aggressive prostate cancer, eliminate need for some biopsies
A home urine test demonstrated high sensitivity for detection of aggressive prostate cancer, according to study findings.The approach may help some men with lower risk…
Therapy for MYD88 L265P DLBCL
In this issue of Blood, Li et al report their finding that the small molecule compound lasalocid A specifically targets mutated MYD88 L265P protein in diff
Accelerated Approvals in Oncology (1992 – Present) – Friends of Cancer Research
Using publicly available data from review documents on Drugs@FDA and information listed in FDA’s public database on post-market requirements (PMRs) Friends created this dashboard to…
Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T
During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction…
